Indian MNC Stocks With Growing Global Revenue Exposure

Indian multinational corporations are stepping up overseas expansion just as record outbound investments, foreign investor outflows of over $23b and a rupee that has weakened more than 6% against the dollar are reshaping the risk and reward trade off for global exposure. For investors, this mix of currency pressure, large cross border deals such as Sun Pharma’s planned Organon purchase and Persistent Systems’ bid for Nagarro, and near zero net FDI inflows creates both potential cushions and fresh risks. This article walks through 3 stocks from the Indian MNCs Expanding Overseas theme that appear positively exposed to these trends.

Hitachi Energy India (NSEI:POWERINDIA)

Overview: Hitachi Energy India designs, manufactures, and services high voltage equipment and digital solutions that keep electricity flowing across grids, rail, data centers, and industrial sites in India and overseas, backed by engineering, installation, and lifecycle support for complex power projects.

Operations: Hitachi Energy India generates its revenue primarily from its Power Grids segment, which reported ₹81,477.1 million.

Market Cap: ₹1.51t

Hitachi Energy India operates at the center of India’s grid upgrade and export initiatives, with a record order backlog tied to transmission projects, data centers, metros, and a multiyear ₹4,000 crore capacity build out that supports both domestic demand and overseas orders. The company is also focusing on higher margin digital and automation solutions. These, together with rapid earnings and revenue growth and improved profit margins, help explain why analysts are comfortable with rich valuation multiples and a high P/E. At the same time, elevated royalty and administrative costs, dependence on large HVDC projects, and reliance on external borrowing mean the story involves risks, especially as the rupee and global trade conditions remain important factors.

Hitachi Energy India’s rich P/E and heavy capex plan make sense only if the story holds together over the full cycle. Before you decide where you stand, review the 2 key rewards and 1 important major warning sign

J. B. Chemicals & Pharmaceuticals (BSE:506943)

Overview: J. B. Chemicals & Pharmaceuticals develops and sells branded medicines, herbal remedies, and active pharmaceutical ingredients across a wide range of therapies in India and overseas, supplying everything from tablets and injectables to contrast media for x ray, MRI, and ultrasound imaging.

Operations: J. B. Chemicals & Pharmaceuticals generates its revenue primarily from Pharmaceuticals at ₹41,477.9 million, with sales spread across India at ₹24,735.4 million and outside India at ₹16,742.5 million.

Market Cap: ₹402.3b

J. B. Chemicals & Pharmaceuticals gives you exposure to a diversified pharma business that mixes domestic brands with overseas formulations and a CDMO pipeline, which management expects to carry positive momentum as new contracts are executed. At the same time, the stock trades on a high P/E, earnings in the latest quarter were lower than a year earlier, and the company leans heavily on a handful of key brands while carrying only modest R&D spend and higher risk borrowings. If you want to understand whether the price, export ambitions and integration with Torrent are justified by the long term earnings potential, there is more to unpack in the detailed analysis and risk breakdown.

J. B. Chemicals & Pharmaceuticals sits at the crossroads of premium valuations and an expanding India plus overseas franchise, and the full picture only really comes into view when you read the analysis report for J. B. Chemicals & Pharmaceuticals

Persistent Systems (NSEI:PERSISTENT)

Overview: Persistent Systems is an India headquartered IT services company that helps global clients in BFSI, healthcare, life sciences and technology sectors build and run software, cloud and data platforms, with a growing focus on generative AI through its Persistent GenAI Hub and partnerships with major tech providers.

Operations: Persistent Systems generates most of its revenue from Software, Hi Tech and Emerging Industries at ₹58,829.9 million, followed by BFSI at ₹50,933.0 million and Healthcare & Life Sciences at ₹37,721.7 million, with North America contributing ₹118,935.5 million of its geographic revenue.

Market Cap: ₹757.6b

Persistent Systems is notable in the overseas expansion theme because a large share of its income already comes from international clients, it is leaning into AI with offerings such as its GenAI Hub, and it has been active in cross border deals including the proposed €1.3b Nagarro acquisition and the Concise integration in Eastern Europe. Earnings growth has outpaced many IT peers, margins are in the low teens and return on equity is above 20%. At the same time, the stock trades on a rich P/E and relies fully on external borrowing for its liabilities, while customer concentration in BFSI and healthcare adds another layer of risk. How these factors interact when the rupee is under pressure and outbound M&A is accelerating is a key part of the investment debate on Persistent.

Persistent Systems already has rich P/E multiples, international exposure and a push into GenAI. Yet the real story sits in how earnings expectations stack up against that price. Get the full picture in the analyst forecasts for Persistent Systems

The three stocks covered here are just a starting point, and the full Indian Multinational Corporations (MNCs) Expanding Overseas screener surfaces 29 more Indian companies expanding overseas with equally compelling multinational narratives. Use Simply Wall St to identify and analyze the specific catalysts and storylines that matter to you so you can focus on the highest conviction opportunities within this theme.

Take Control of Your Investment Journey

If Persistent Systems or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Stocks?

Fresh ideas often move first when momentum builds, and the best entry points can pass quickly before the crowd reacts. Scan these under the radar lists now to explore potential opportunities earlier in the cycle.

• Identify companies with strong cash positions and disciplined reinvestment by running your own shortlist through the list of solid balance sheet and fundamentals (418 results).
• Follow companies participating in the AI build out while prices still reflect early stage expectations using the curated 52 AI infrastructure stocks.
• Focus on resilient performers that may help moderate portfolio swings by reviewing the hand picked 297 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com